Literature DB >> 1159085

Metabolism of properdin in normal subjects and patients with renal disease.

J B Ziegler, F S Rosen, C A Alper, W Grupe, I H Lepow.   

Abstract

Properdin deposition has been recognized in glomeruli of patients with acute and chronic nephritis and lupus nephritis, and low serum properdin levels have been found in these disorders. These findings suggest that properdin may be involved in the production of glomerular damage and that low properdin levels may be due to hypercatabolism. The study was designed to examine the metabolism of properdin in normal subjects and to look for an abnormality in five patients with systemic lupus erythematosus with renal involvement and in six patients with membranoproliferative glomerulonephritis or dense deposit disease (MPGN). Highly purified human properdin was prepared by elution from zymosan, followed by DEAE-cellulose and carboxymethyl-Sephadex chromatography, and labeled with 125I by the iodine monochloride method. Parameters of metabolism were determined by monitoring plasma and urinary radioactivity at frequent intervals after the intravenous injection of 1-2 muCi of labeled material. The fractional catabolic rate (FCR) of properdin in normal subjects was found to have a very narrow range of 0.78-1.0,% of the plasma pool per hour (mean 0.95%). In systemic lupus erythematosus, the FCR was regularly elevated with a range of 1.21-2.30% (mean 1.70%). In MPGN, FCR was elevated in three patients (1.22, 1.94, and 2.08%) and within or below the normal range in three (0.78, 1.00, and 1.00%). Properdin levels were reduced in two patients who had the highest FCR's noted in the study. Properdin synthetic rates in normals varied from 4.1 to 14.3 mug/kg per h (mean 9.1) and was not found to be reduced in any patient. Properdin catabolism was found to be normal in a patient deficient in the C3b inactivator. These studies show that properdin is hypercatabolized in patients with renal disease and that decreased properdin levels when they occur in these patients can be entirely explained on the basis of this hypercatabolism.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159085      PMCID: PMC301925          DOI: 10.1172/JCI108147

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

Review 1.  Analysis of disappearance time-curves after single injection of labelled proteins.

Authors:  B Nosslin
Journal:  Ciba Found Symp       Date:  1972

2.  Properties of highly purified human properdin.

Authors:  J Ensky; C F Hinz; E W Todd; R J Wedgwood; J T Boyer; I H Lepow
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

3.  The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.

Authors:  A E Stitzel; R E Spitzer
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

4.  Glomerular and dermal depostion of properdin in systemic lupus erythematosus.

Authors:  N Rothfield; H A Ross; J O Minta; I H Lepow
Journal:  N Engl J Med       Date:  1972-10-05       Impact factor: 91.245

5.  Studies on the sub-unit structure of human properdin.

Authors:  J O Minta; I H Lepow
Journal:  Immunochemistry       Date:  1974-07

6.  Properdin levels in systemic lupus erythematosus and membranoproleferative glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  Clin Exp Immunol       Date:  1974-04       Impact factor: 4.330

7.  Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

Authors:  J B Ziegler; C A Alper; R S Rosen; P J Lachmann; L Sherington
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

8.  Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis.

Authors:  R H McLean; A F Michael
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

9.  Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.

Authors:  C A Alper; N Abramson; R B Johnston; J H Jandl; F S Rosen
Journal:  J Clin Invest       Date:  1970-11       Impact factor: 14.808

10.  The role of properdin in the alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1974-01-01       Impact factor: 14.307

View more
  14 in total

1.  Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema.

Authors:  M Quastel; R Harrison; M Cicardi; C A Alper; F S Rosen
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

2.  Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

3.  Activation of the alternative complement pathway in systemic lupus erythematosus.

Authors:  M R Wilson; C M Arroyave; R M Nakamura; J H Vaughan; E M Tan
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

4.  Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.

Authors:  D Adu; D G Williams
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

5.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

6.  Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.

Authors:  M T Aguado; L H Perrin; R Ramirez; P A Miescher; P H Lambert
Journal:  Clin Exp Immunol       Date:  1980-12       Impact factor: 4.330

7.  Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

Authors:  J T Mayes; R D Schreiber; N R Cooper
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

8.  Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; J Hermans; L A van Es; A Cats
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

9.  Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis.

Authors:  K Whaley; D Ward; S Ruddy
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

10.  Clinical and functional consequences of anti-properdin autoantibodies in patients with lupus nephritis.

Authors:  M Radanova; G Mihaylova; D Ivanova; M Daugan; V Lazarov; L Roumenina; V Vasilev
Journal:  Clin Exp Immunol       Date:  2020-05-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.